Related Experiment Video

Updated: Aug 20, 2026

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice
07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

[Calcium antagonists: anti-atherosclerotic effect by modification of the prostaglandin system]

K Weiss1

  • 1Atheroskleroseforschungsgruppe, Wien.

Wiener Klinische Wochenschrift
|November 4, 1988
PubMed

Insights

Calcium blockers like isradipine, nifedipine, diltiazem, and verapamil inhibit platelet activation and enhance prostaglandin PGI2 formation. These effects suggest a potential benefit against atherosclerosis.

Area of Science:

  • Cardiovascular Pharmacology
  • Platelet Physiology
  • Prostaglandin Biology

Context:

  • Atherosclerosis involves platelet activation and vascular dysfunction.
  • The prostaglandin system plays a crucial role in regulating platelet and vascular functions.
  • Calcium channel blockers are widely used for cardiovascular conditions.

Purpose:

  • To investigate the impact of four calcium channel blockers (diltiazem, isradipine, nifedipine, verapamil) on the prostaglandin system in blood platelets and the vessel wall.
  • To assess the potential anti-atherosclerotic effects of these blockers through their influence on platelet aggregation, thromboxane production, and prostacyclin formation.

Summary:

  • In vitro studies showed all tested calcium blockers dose-dependently inhibited platelet activation, malondialdehyde formation, and thromboxane B2 production, with isradipine being most potent.
  • Vascular prostacyclin (PGI2) formation in rat aortic rings was enhanced by all calcium blockers, again with isradipine showing the most significant effect.
  • Ex vivo studies after oral administration demonstrated reduced ADP- and epinephrine-induced platelet aggregation and serum thromboxane levels, suggesting a beneficial cardiovascular profile.

Impact:

  • These findings indicate that calcium channel blockers may exert beneficial effects on atherosclerosis by modulating the prostaglandin system.
  • The study highlights the differential effects of various calcium blockers on platelet and vascular functions, with implications for therapeutic strategies.
  • Further research is warranted to confirm these cardioprotective mechanisms in clinical settings.

More Related Videos

A Calcium Phosphate-Induced Mouse Abdominal Aortic Aneurysm Model05:14

A Calcium Phosphate-Induced Mouse Abdominal Aortic Aneurysm Model

Published on: November 18, 2022

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...